AIM:AGY

Allergy Therapeutics PLC

Market:

AIM

Market Cap:

£67.43 m

Price

10.60 GBX

Change

0.00%

52 weeks high

16.60

52 weeks low

8.00

06.04

Director Interviews

In brief

We are a market leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Allergy Therapeutics: Profitable, growing and with product pipeline not to be sneezed at

Allergy Therapeutics PLC -

Snapshot

Profitable allergy specialist developing new inoculations
Full-year results exceeded expectations
Strong pipeline of new products under development

Interviews

Allergy Therapeutics PLC - Allergy Therapeutics confident on the coming year as it reports 8% boost to revenues

Health Allergy Therapeutics confident on the coming year as it reports 8% boost to revenues

on 25/9/19

Retail & consumer Benchmark Holdings identifies breakthrough to help Tilapia fight disease

on 11/7/19

Health Allergy Therapeutics expects earnings to come in ahead of market expectations

on 11/7/19

Retail & consumer Investor Update: Allergy Therapeutics receives multi-million-dollar settlement

on 27/6/19

Follow us on:

© Proactive Investors 2019.

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.